CRISPR Therapeutics (NASDAQ:CRSP) Issues Quarterly Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings results on Tuesday. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $39.62 on Wednesday. The company has a fifty day moving average of $42.45 and a two-hundred day moving average of $46.40. The stock has a market capitalization of $3.38 billion, a PE ratio of -14.00 and a beta of 1.67. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on CRSP. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. JMP Securities reissued a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday. Finally, HC Wainwright began coverage on CRISPR Therapeutics in a research note on Monday, February 3rd. They set a “buy” rating and a $65.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $75.22.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.